Bobby Defino, Creative Director, Designer

This HCP unbranded disease awareness campaign introduces the science behind bluebird bio's LentiGlobin (lentivirus vector) gene therapy as a transforming new alternative for a number of diseases including sickle cell.

Approximately 100,000 people live with sickle cell in the US, most of whom are African American. There remains a profound unmet need surrounding this underserved population.

The campaign underscores bluebird bio's commitment to a global community of HCP/hematologists, cultural leaders, caregivers, patients and families.

SHIRE funded this Disney-inspired experience to introduce VYVANSE, a prodrug for ADHD, demonstrating how it works differently.

An animated character named VANSE assists the moderator in presenting the MOD science of VYVANSE. Separate presentation cuts tailored for specific audiences, included HCPs, patients, caregivers, and internal SHIRE staffers.

Ovarian cancer remains the deadliest gynecologic cancer with an estimated 22,000 new diagnoses each year in the US.

In preparation for the launch of ZEJULA, a promising new oral PARP inhibitor for recurrent epithelial ovarian cancer, TESARO commissioned this #WhoInspiresYouOC awareness campaign featuring patient correspondence.

The vaginal speculum continues to rely on a design invented 200 years ago. With a reputation for discomfort and anxiety, words such as clank, click, and pinch are used by women to describe their experience.

CEEK launched a revolutionary new line of NELLA women’s health products delivering a gentler, more ergonomic exam experience for patients and clinicians.

With a core executive team of women, from experienced designers to health care experts, CEEK brings a woman’s perspective to the OBGYN field.

When cells become cancerous, they are 100 times more likely to mutate than normal cells. This is especially true in non-small cell lung cancer (NSCLC).

T790M is an EGFR mutation that surfaces after the use of early generation targeted therapies in a significant number of people.

In preparation for product launch, Clovis Oncology commissioned this disease education campaign to shed light on T790M, a promising therapeutic target.

Close to 16 million American’s have chronic obstructive pulmonary disease (COPD). A significant challenge for primary care physicians is diagnostic confusion between the complexities of COPD and asthma.

GSK launched this HCP peer-to-peer disease awareness video campaign to support their respiratory franchise featuring new triple-therapy TRELEGY.

The program provides PCPs an opportunity to reduce the potential for unnecessary or sub-optimal care while improving outcomes.

Oral immunotherapy (OIT) for food allergies has been around for over 100 years. Fewer than 20% of allergists today consider OIT a viable alternative due to the absence of a clinically validated protocol. Many HCPs describe practicing OIT as walking a tight rope.

AIMMUNE Therapeutics recently launched CODIT, a new standardized OIT stepped platform set to become the foundation for future OIT branded therapies for food allergies–beginning with PALFORZIA for peanut in 2020.

CODIT Step Up campaign imagery features a physician high above a cityscape embedded with eight of the most aggressive, ever-present food allergies.

The FDA recently approved KITE PHARMA's TECARTUS, the first and only CAR-T cell treatment for relapsed or refractory mantle cell lymphoma (MCL).

ZUMA-2 study results are outstanding with 87% response to a single infusion. And 62% achieving a complete response.

This launch marks a historic moment for KITE PHARMA, in having now established the first-ever CAR-T franchise. These video presentations were part of a more considerable virtual launch meeting effort supporting TECARTUS approval announcement, marketing, and sales efforts.

Research with HCPs and patients reveals that metastatic breast cancer patients who pay attention to dress and grooming are excellent candidates for aggressive late-stage agents like IXEMPRA.

Along with new HCP and patient brand campaigns, a disease awareness corporate effort announced the IXEMPRA purchase by R-PHARM US from BMS.

Additionally, R-PHARM US sponsored lookgoodfeelbetter.org, a non-profit which teaches techniques to counter appearance-related side effects.

PatientCentral is a corporate communication campaign designed to streamline and organize TAKEDA's internal communication platform.

Along with providing daily access to scientific advance updates, PatientCentral fosters more meaningful and rewarding connections between TAKEDA's 30,000 employees worldwide.

PatientCentral spotlights individual accomplishments by connecting TAKEDA's people with ongoing patient success stories.

Colorectal cancer is the third most common cancer in both men and women worldwide. AMGEN's product VECTIBIX is the first anti-EGFR approved in combo with first-line chemo.

Whatsmore, VECTIBIX powerfully targets WT (wild-type) RAS mCRC (metastatic colorectal cancer) aggressive tumor growths.

This unique branding campaign for VECTIBIX conjures an immediate sense of urgency with HCPs seeking rapid reduction in tumor burden.

NUCLEUS GLOBAL is a believer in intern programs. Drawing perspective from anyone outside the industry, team, or day-to-day operations encourages surprising inspiration.

By design, this 2020 social campaign series reached out to various subsets of intern candidates. From those inspired by scientific adventure to those seeking an exciting summer job with pay to those building their career.

Despite COVID, it was the most successful recruiting ever. Best of all, exponential positives throughout the social community followed.

With a rich history dating back over 25 years, Pfizer’s Inflammation & Immunology scientific affairs group is a world leader in janus kinase (JAK) inhibition.

Pfizer commissioned this engaging interactive timeline for both live exhibits and virtual applications, featuring a combination of AR and mixed media.

Highlighted is Pfizer’s advancing JAK pathway science, with breakthroughs in multiple rheumatology, dermatology, and gastroenterology disease states.

This science-fiction-styled self-promotion campaign aided NAVICOR in building awareness for the agency and recruiting talent.

Suggested is the intriguing notion of joining a scientifically-advanced society with the ambition and desire to envision and embrace its future. The illuminated “O” reinforces NAVICOR’s focus on oncology.

This dramatic HCP/DTC unbranded campaign builds awareness for stopdvt.org, a disease education site sponsored by SANOFI. The goal, to protect and educate against the devastating effects of DVT or deep vein thrombosis.

DVT is often silent and can attack without noticeable symptoms. There are many risk factors, including the simple act of prolonged inactivity—for example, a long plane ride. Even the healthiest of individuals can fall prey.

This HCP symposium theme introduces the AD Continuum, new science from BMS taking a fresh look at Alzheimer’s Disease progression.

A multi-faceted campaign series with this award-winning core imagery supports ongoing BMS event promotion and data delivery connected with new therapeutic pathways in AD.

Meet Digger the Dermatophyte, the personification of annoying, irritating, difficult-to-treat fungal infection. In short, a persistent pest.

Digger initially supported LAMISIL TABLETS for nail fungus (onychomycosis), particularly invasive and often returning after treatment.

Eventually, Digger spread to the entire LAMISIL antifungal product line, helping build a billion-dollar NOVARTIS (now GSK) global franchise.

This Webby-winning interactive series of animated modules helped HCPs to better understand the renin-angiotensin-aldosterone system (RAAS) in this unbranded educational experience sponsored by NOVARTIS.

The program supported several Novartis cardiovascular agents, including ENTRESTO for long-lasting, (chronic) heart failure.